Doxirubicin has been shown to significantly improve survival times for cats with colonic adenocarcinoma with median survival times of 56 and 280 days for those not receving and those receiving chemotherapy respectively. No other evidence exists to confirm the benefits of adjuvant chemotherapy in dogs or cats. Piroxicam, a non-steroidal anti-inflammatory drug may have beneficial effects for rectal malignancy.
+
Doxirubicin has been shown to significantly improve survival times for cats with colonic adenocarcinoma with median durations of 56 and 280 days for those not receving and those receiving chemotherapy respectively. No other evidence exists to confirm the benefits of adjuvant chemotherapy in dogs or cats. Piroxicam, a non-steroidal anti-inflammatory drug may have beneficial effects for rectal malignancy.